A federal district court in California granted in part and denied in part Corcept Therapeutics Inc. and Optime Care Inc.'s motion to dismiss Teva Pharmaceuticals USA Inc.'s action alleging anti-competitive practices related to Corcept’s drug used to treat endogenous Cushing’s syndrome. The court said that Teva alleged an exclusive agreement and substantial market foreclosure, and partially demonstrated monopolization and attempted monopolization.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.